The NMDA Hypofunction Model: What Ketamine Research Shows

The NMDA hypofunction model of psychosis is a research framework built largely from studies that gave ketamine to healthy volunteers and recorded how it temporarily disrupted glutamate signaling in the brain. Researchers use the model to study why reduced activity at N-methyl-D-aspartate (NMDA) receptors, a subtype of glutamate receptor, can produce symptoms that resemble schizophrenia, including hallucinations, paranoia, blunted emotion, and working-memory deficits. The model does not claim that ketamine causes schizophrenia or that a single ketamine session diagnoses psychosis. It uses ketamine's short, reversible receptor-blocking action as a controlled laboratory tool to probe the glutamate system's role in psychotic symptoms, a role that researchers view as complementary to the longer-standing dopamine hypothesis of schizophrenia.

What NMDA Receptors Do in the Brain

Glutamate is the brain's main excitatory neurotransmitter, and the NMDA receptor is one of the main docking sites glutamate binds to. NMDA receptors help regulate synaptic plasticity, the process by which connections between neurons strengthen or weaken, which underlies learning, memory, and sensory processing. When NMDA receptor activity drops below normal levels, a state researchers call NMDA hypofunction, downstream glutamate signaling becomes disorganized rather than simply reduced. That disorganization, not a straightforward deficiency, is what researchers believe drives the psychosis-like effects seen in laboratory studies.

Ketamine blocks NMDA receptors in a noncompetitive, dose-dependent way, meaning it attaches to a site on the receptor and prevents it from functioning normally regardless of how much glutamate is present. At the low, subanesthetic doses used in research settings, this produces temporary effects without the full anesthesia seen at higher clinical or surgical doses. For background on how dose and route affect what ketamine does in the body, see ketamine pharmacology and how effects track with ketamine half-life by route of administration.

How Ketamine Research Built the Model

The NMDA hypofunction model grew out of decades-old observations about phencyclidine (PCP), another NMDA receptor antagonist, which produced psychosis-like reactions in people who used it recreationally starting in the 1960s. Psychiatrists Daniel Javitt and Stephen Zukin formalized the glutamate-based theory in a widely cited 1991 paper in the American Journal of Psychiatry, indexed on PubMed, arguing that PCP's effects pointed to a receptor system beyond dopamine that was relevant to schizophrenia.

Ketamine, a shorter-acting and more controllable NMDA antagonist than PCP, became the preferred research tool through the 1990s. A frequently cited 1994 study led by John Krystal and colleagues at Yale, published in Archives of General Psychiatry and indexed on PubMed, gave healthy volunteers a series of subanesthetic ketamine doses and measured dose-dependent increases in psychotomimetic symptoms, dissociative effects, and performance deficits on tests of working memory and abstract reasoning.

What the Model Does and Doesn't Explain

Researchers treat NMDA hypofunction as one contributor to psychosis, not a full explanation. Most schizophrenia researchers view the glutamate-based model as complementary to the longer-standing dopamine hypothesis, since the two neurotransmitter systems interact, rather than as a replacement for it. Pharmaceutical companies used the NMDA hypofunction model to design drugs targeting the glycine site on NMDA receptors and group II metabotropic glutamate receptors, hoping to treat schizophrenia symptoms without the side effects of dopamine-blocking antipsychotics. Several of those candidates showed promise in early trials but failed to outperform placebo in larger, later-phase studies, a pattern that illustrates the limits of translating a laboratory model into an approved treatment. If you want to evaluate claims from studies like these yourself, see how to read ketamine depression research studies for questions to ask about sample size, dosing, and follow-up.

Research Doses vs. Therapeutic Doses

The subanesthetic doses used in NMDA hypofunction studies overlap with the dose range used off-label for depression and the dose range used for esketamine (Spravato), which is FDA-approved for treatment-resistant depression and administered under a Risk Evaluation and Mitigation Strategy (REMS). See Spravato REMS requirements explained for details. That overlap is why dissociation and transient perceptual changes show up on the safety checklist clinicians monitor during and after dosing, not because the treatment is intended to induce psychosis. Ketamine's active metabolites, described in more detail in ketamine metabolites: norketamine and hydroxynorketamine, also factor into how long these effects last and how they differ across routes of administration. Researchers sometimes use the term k-hole informally to describe the intense dissociative state at higher doses, which is distinct from the controlled, lower-dose psychotomimetic effects studied in NMDA hypofunction research.